HeartBeam Receives FDA Clearance for First-Ever, Cable-Free Synthesized 12-Lead ECG for At-Home Arrhythmia Assessment ...
Standard ADC components seldom provide enough flexibility to meet the conflicting needs of today’s medical designs. By Ian ...
Press Trust of India on MSN
OMRON Healthcare unveils global ECG strategy
OMRON Healthcare Co., Ltd. announced new initiatives to accelerate its global electrocardiogram (ECG) business strategy, ...
TipRanks on MSN
HeartBeam (NASDAQ: BEAT) secures FDA 510(k) clearance for 12-lead ECG synthesis software following successful appeal
Austin, Texas, United States, December 10th, 2025, FinanceWire HeartBeam (NASDAQ: BEAT), a medical technology company focused ...
We've read the fine print -- and consulted experts -- about Apple's irregular heart rhythm technology so you don’t have to. Danielle Kosecki is an award-winning journalist who has covered health and ...
HeartBeam's 1st synthesized 12-lead ECG cleared by FDA, enabling cable-free at-home arrhythmia assessment with launch set for 2026.
Andrew Simpson, CEO of HeartSciences said, “MyoVista Insights is a state-of-the-art ECG reporting and management platform that delivers substantial clinical, operational, and data-security benefits ...
A new Concordia study published in npj Biomedical Innovations suggests that a simple 30-second electrocardiogram (ECG) ...
HeartBeam (Nasdaq:BEAT) announced today that it received FDA 510(k) clearance for its 12-lead electrocardiogram (ECG) ...
HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through personalized insights, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback